Allain, Eric P.
Rouleau, Michèle
Lévesque, Eric
Guillemette, Chantal
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (FRN#42392, FRN#142318, FRN#152986)
Article History
Received: 7 August 2019
Revised: 6 December 2019
Accepted: 17 December 2019
First Online: 12 February 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Not applicable.
: The authors declare no competing interests.
: This research was supported by the Canadian Institutes of Health Research (CIHR; C.G.: FRN#42392; FRN#142318; FRN#408093; C.G. and E.L.: FRN#152986) and the Canada Research Chair in Pharmacogenomics (Tier I) to C.G. E.P.A. received scholarships from Foundation of University Laval—Leadership and sustainable development award, CHU de Québec Foundation—Fernand Labrie excellence award and the Fonds de Recherche du Québec—Santé. EL received a CIHR phase II clinician–scientist award.